Clinical trials: Atorvastatin
Hyperlipidemias
A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants
This phase I study in healthy participants aims to assess the pharmacokinetics of midazolam and atorvastatin when administered alone and in combination with HRS-1301, and to assess the safety of HRS-1301 when administered alone…
- Trial name
- NCT07608705
- Testing
- HRS-1301 Tablets, Atorvastatin Calcium Tablets, Midazolam oral solution
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Hyperlipidemia
A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin
The objective of this study is to evaluate the effects of adding Tricor 145 mg to once daily atorvastatin 20 mg on CHD lipid laboratory parameters.
- Trial name
- NCT00195793
- Testing
- fenofibrate, ezetimibe, atorvastatin
- Volunteers
- 174 people
- Sponsor
- Abbott
Hypertension, Hyperlipidemia
Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia
The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.
- Trial name
- NCT01442987
- Testing
- Irbesartan/Atorvastatin A, Irbesartan, Atorvastatin A
- Where
- South Korea
- Volunteers
- 230 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Dyslipidemia
An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With Dyslipidemia
In this study, dyslipidemia patients visited the institutions during the study period and the effectiveness and safety of the treatment of Newvast® Tab(Atorvastatin) in real-practice.
- Trial name
- NCT05555238
- Testing
- single arm, single group(No interventional)
- Where
- South Korea
- Volunteers
- 1,716 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Cardiovascular Disorder, Diabetes Mellitus
Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COMPLETED)
The purpose of this study is to determine the efficacy of switching to a combination tablet ezetimibe/simvastatin (10mg/20mg) versus rosuvastatin (10 mg) versus doubling the statin dose in those patients who have cardiovascular…
- Trial name
- NCT00862251
- Testing
- ezetimibe (+) simvastatin, simvastatin 40 mg or atorvastatin 20 mg, Rosuvastatin
- Volunteers
- 808 people
- Sponsor
- Organon and Co
Hypercholesterolemia, Dyslipidemias
A Study to Evaluate the Effectiveness and Safety of Fixed-Dose Combination of Pitavastatin/ Ezetimibe
The objective of this study is to evaluate the effectiveness and safety of Pitavastatin/Ezetimibe FDC in patients with hypercholesterolemia.
- Trial name
- PIVOTAL (NCT07083206)
- Where
- South Korea
- Volunteers
- 4,500 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Hypercholesterolemia
Efficacy and Safety Study of Pitavastatin Versus Atorvastatin to Treat Hypercholesterolemia
Statin is an effective drug to treat hyperlipidemia (hypercholesterolemia), and it rarely leads to hepatic damage to the patients with hepatic disorder. For these patients, intensive monitoring is required.
- Trial name
- PITCH (NCT01166633)
- Testing
- pitavastatin, atorvastatin
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
Hypercholesterolemia
Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)
The purpose of this study is to determine whether an investigational medication will be more effective than an approved medication in reducing cholesterol levels.
- Trial name
- NCT00092716
- Testing
- MK0653, ezetimibe / Duration of Treatment: 28 weeks, Comparator: atorvastatin / Duration of Treatment: 28 weeks
- Volunteers
- 655 people
- Sponsor
- Organon and Co
Type IIa and IIb Hypercholesterolaemia
Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients
The purpose of this study is to evaluate the efficacy and safety of Rosuvastatin 5 mg as an hypercholesterolemia treatment comparatively at 2 other statins: Pravastatin 40 mg and Atorvastatin 10 mg.
- Trial name
- CAP-Chol (NCT00631189)
- Testing
- Rosuvastatin, Pravastatin, Atorvastatin
- Where
- 170 sites in France
- Volunteers
- 668 people
- Sponsor
- AstraZeneca
Mixed Hyperlipidemia
Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia
- Trial name
- RADIANCE 2 (NCT00134238)
- Testing
- torcetrapib/atorvastatin, atorvastatin
- Where
- 51 sites in United States, Canada and 4 more
- Volunteers
- 755 people
- Sponsor
- Pfizer
Hyperlipidemia
Assess HDL-C Increase And Non-HDL Lowering Effect Of Torcetrapib/Atorvastatin Vs. Fenofibrate
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the HDL-C increase and non-HDL lowering effect of torcetrapib/atorvastatin vs. fenofibrate.
- Trial name
- NCT00139061
- Testing
- Torcetrapib/Atorvastatin, Fenofibrate
- Where
- 26 sites in France
- Volunteers
- 128 people
- Sponsor
- Pfizer
Hypercholesterolemia
A Study in People With High Cholesterol
The purposes of this study are to determine: The safety of the study medication and any side effects that might be associated with it Whether the study medication can help patients with high levels of "bad" cholesterol…
- Trial name
- NCT00133380
- Testing
- PPAR alpha, atorvastatin
- Where
- 28 sites in United States
- Volunteers
- 300 people
- Sponsor
- Eli Lilly and Company
Essential Hypertension, Primary Hypercholesterolemia
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'.
This prospective study aims to observe changes in renal function and related parameters in patients with essential hypertension and primary hypercholesterolemia receiving either the combination of fimasartan and atorvastatin or…
- Trial name
- NCT07685054
- Volunteers
- 12,700 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypercholesterolemia in Coronaory Heart Disease
Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases
To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in combination with Atorvastatin in subjects with hypercholesterolemia and coronary…
- Trial name
- HS-25-III-02 (NCT03433196)
- Testing
- HS-25 and Atorvastatin, Atorvastatin
- Volunteers
- 255 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Hypercholesterolemia
Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
This study will evaluate the EZ/Ator fixed-dose combination (FDC) tablet (MK-0653C) as second line Low-Density Lipoprotein - Cholesterol (LDL-C) treatment in Chinese participants.
- Trial name
- NCT03768427
- Testing
- EZ 10 mg/Ator 10 mg, EZ 10 mg/Ator 20 mg, Atorvastatin
- Where
- 30 sites in China
- Volunteers
- 454 people
- Sponsor
- Organon and Co
Myalgia, Hypercholesterolemia
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
The purpose of this study is to assess the incidence of statin-associated myalgia (SAM) with treatment with PPD10558 versus atorvastatin in patients previously intolerant to statins.
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT01279590
- Testing
- PPD10558, Atorvastatin
- Where
- 67 sites in United States
- Volunteers
- 282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Healthy Volunteers, Pharmacokinetics
Drug Interaction Study - Assess Pharmacokinetics of Both AZD5672 and Atorvastatin
The purpose of the study is to assess the pharmacokinetics of both AZD5672 (steady-state) and atorvastatin (single dose) when co administered in healthy volunteers
- Trial name
- NCT00722956
- Testing
- AZD5672, atorvastatin
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diseases of the Circulatory System, Essential Hypertension
To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers
The study design was composed of 2 parts, 2-way crossover and multiple-dose. There are having 2 groups in each part that have divided period 1 and period 2, and wash-out period is 16 days between periods.
- Trial name
- NCT02579356
- Testing
- Telmisartan, Atorvastatin
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Samil Pharmaceutical Co., Ltd.
Hyperlipidemias
A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol
The purpose of this study is to evaluate the efficacy and safety of atorvastatin for the treatment of Taiwanese patients with diabetes and high cholesterol.
- Trial name
- NCT00645424
- Testing
- atorvastatin
- Where
- 5 sites in Taiwan
- Volunteers
- 155 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypercholesterolemia
Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet
To determine whether new 10 mg atorvastatin tablets are bioequivalent to 10 mg commercial atorvastatin tablets (Lipitor®).
- Trial name
- NCT00917579
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.